ClinicalTrials.gg
Active, not recruitingNCT04708041Updated Apr 20, 2025

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

A Phase 3 interventional study of 9vHPV vaccine in Papillomavirus Infections, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 30 sites in 6 countries. Open to participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
9 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Planned enrollment
16th of 31
700 · median 700
Started
2021
with 3 others
Phase 3
16 of 31
2 open now
Primary completion
2029-10
later than 18 of 19 live
Registered
15th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 16th largest by planned enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, reaches primary completion later than 18 of the 19 other live ones, and was the 15th registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal is to establish that the investigational extended 2-dose regimens (0, 12 months; 0, 24 months; 0, 36 months; and 0, 60 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who receive the standard 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine at 0, 2, and 6 months (i.e., the population and dose regimen used to establish 9vHPV vaccine efficacy).

03

Conditions studied

  • Papillomavirus Infections
04

Who can participate

Ages eligible
9 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Boys and Girls 9 to 15 Years:

  • Must not have had coitarche and does not plan on becoming sexually active during the vaccination period

Women 16 to 26 Years:

  • Has never had a Papanicolaou (Pap) test or only had normal Pap test results
  • A lifetime history of 0 to 4 male and/or female sexual partners

Cohort 0 Participants:

  • Received 1 dose of 9vHPV vaccine at least 1 year prior to enrollment and did not receive a second dose of any HPV vaccine

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Known allergy to any vaccine component
  • History of severe allergic reaction that required medical intervention
  • Thrombocytopenia or any coagulation disorder
  • Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7
  • Currently , or been diagnosed with immunodeficiency
  • Had a splenectomy
  • Receiving or has received immunosuppressive therapies within the last year
  • Received any immunoglobulin product or blood-derived product within 3 months
  • Has received more than 1 dose of an HPV vaccine (Cohort 0)
  • Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial (Cohorts 1-5)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Cohort 0: 1 Dose of 9vHPV Vaccine (previous 1-dose recipients)

    10 to 15 year old girls and boys (who previously received 1 dose of 9vHPV vaccine) receive a second dose of 9vHPV vaccine at Day 1.

    Biological: 9vHPV vaccine

  • Experimental
    Cohort 1: 2 Doses of 9vHPV Vaccine Given 12 Months Apart

    9 to 14 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 12.

    Biological: 9vHPV vaccine

  • Experimental
    Cohort 2: 2 Doses of 9vHPV Vaccine Given 24 Months Apart

    9 to 13 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Months 24.

    Biological: 9vHPV vaccine

  • Experimental
    Cohort 3: 2 Doses of 9vHPV Vaccine Given 36 Months Apart

    9 to 12 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 36.

    Biological: 9vHPV vaccine

  • Experimental
    Cohort 4: 2 Doses of 9vHPV Vaccine Given 60 Months Apart

    9 to 10 year old girls and boys receive a 2-dose regimen of 9vHPV vaccine at Day 1 and Month 60.

    Biological: 9vHPV vaccine

  • Active comparator
    Cohort 5: 3 Doses of 9vHPV Vaccine Given Over a 6-Month Period

    16 to 26 year old young women receive 3 dose regimen of 9vHPV vaccine at Day 1, Month 2 and Month 6.

    Biological: 9vHPV vaccine

Interventions

  • Biological9vHPV vaccine

    9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers of Anti-Human Papilloma Virus Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 as Measured by Competitive Luminex Immunoassay

    Serum antibody titers for human papilloma virus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using competitive luminex immunoassay (cLIA). The geometric mean titer (GMT) for each HPV type will be reported in milli Merck units/mL (mMU/mL).

    Time frame: 4 weeks post last vaccination (Up to ~Month 61)

  2. Percentage of Participants With at Least 1 Solicited Injection-site Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with injection-site AEs (erythema/redness, pain and swelling) will be assessed.

    Time frame: Up to 5 days post vaccination

  3. Percentage of Participants With at Least 1 Systemic Adverse Event

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with a systemic AE will be assessed.

    Time frame: Up to 15 days post vaccination

  4. Percentage of Participants With at Least 1 Serious Vaccine-Related Adverse Event

    A serious adverse event (SAE) is defined as one that results in death, is life threatening, or requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or other important medical event that may require medical intervention. An SAE that is judged by the investigator to be related to the study vaccine is defined as a vaccine-related SAE.

    Time frame: Entire study period (Up to ~Month 96)

Secondary outcomes

  1. Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.

    Time frame: 4 weeks post last vaccination

  2. Geometric Mean Titers (Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.

    Time frame: 12 months post last vaccination

  3. Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.

    Time frame: 12 months post last vaccination

  4. Geometric Mean Titers ( Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.

    Time frame: 24 months post last vaccination

  5. Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.

    Time frame: 24 months post last vaccination

  6. Geometric Mean Titers ( Cohorts 1 to 5) of Anti HPV Types 6, 11, 16, 18, 31, 33, 45, 52 , and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The GMT for each HPV type (analysis population Cohorts 1 through 5 only) will be reported in mMU/mL.

    Time frame: 36 months post last vaccination

  7. Percentage of Participants (Cohorts 1 to 5) Who Are Seropositive for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 will be determined using cLIA. The percentage of participants who are seropositive (analysis population Cohorts 1 through 5 only) for each HPV type will be assessed.

    Time frame: 36 months post last vaccination

07

Study locations

30 sites
08

References and documents

Publications

  • Teppler H, Bautista O; Thomas Group; Flores S, McCauley J, Luxembourg A. Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. Contemp Clin Trials. 2021 Jun;105:106403. doi: 10.1016/j.cct.2021.106403. Epub 2021 Apr 12. PubMed 33857679 ↗
  • Klein NP, Wiesner A, Bautista O, Group T, Kanu K, Li ZL, McCauley J, Saxena K, Tota J, Luxembourg A, Bonawitz R. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 1;154(2):e2023064693. doi: 10.1542/peds.2023-064693. PubMed 38978512 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Oct 2029, 103 months after the start.

Of 54 industry-sponsored phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 64. This study's planned 103 months is above that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 13, 2021
StartActual
Mar 15, 2021
Primary completionEst.
Oct 23, 2029
CompletionEst.
Oct 23, 2029
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04708041
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Mar 15, 2021
Primary completion
Oct 23, 2029 (estimated)
Completion
Oct 23, 2029 (estimated)
Last update
Apr 20, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion